reports
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in ...
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for oral abstract presentation at ASCO 2024 Annual Meeting with data from approximately 40 patients treated with HB-200 in combination with pembrolizumab Two additional abstracts for HB-200 and HB-700 accepted for the ASCO 2024 Annual Meeting Company to host investor call at 8:0...
Nasdaq Announces 9% Increase in Quarterly Dividend to $0.24 Per Share
Nasdaq Announces 9% Increase in Quarterly Dividend to $0.24 Per Share NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Nasdaq, Inc. (Nasdaq: NDAQ) has declared a regular quarterly dividend of $0.24 per share on the company's outstanding common stock, a 9% increase from the previous quarter. The dividend is payable on June 28, 2024 to shareholders of record at the close of business on June 14, 2024. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by the Board of Directors. About Nasdaq N...
Valley National Bancorp Announces First Quarter 2024 Results
Valley National Bancorp Announces First Quarter 2024 Results NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Valley National Bancorp (NASDAQ:VLY), the holding company for Valley National Bank, today reported net income for the first quarter 2024 of $96.3 million, or $0.18 per diluted common share, as compared to the fourth quarter 2023 net income of $71.6 million, or $0.13 per diluted common share, and net income of $146.6 million, or $0.28 per diluted common share, for the first quarter 2023. Excluding all non-core income and charges, our adjusted net income (a non-GAAP measure) was $99.4 m...
Luk Fook Holdings (International) Ltd: 1 director
A director at Luk Fook Holdings (International) Ltd bought 600,000 shares at 17.957HKD and the significance rating of the trade was 87/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...
Les entreprises du marché français cherchent à tirer davantage de vale...
PARIS--(BUSINESS WIRE)-- Les entreprises du marché français, à la recherche de meilleurs retours sur investissement, se tournent vers des prestataires de services capables de gérer plus efficacement leurs plateformes Salesforce, selon un nouveau rapport de recherche publié aujourd’hui par Information Services Group () (Nasdaq : ), cabinet de conseil et leader mondial de la recherche technologique. Le rapport 2024 ISG Provider Lens™ Salesforce Ecosystem Partners pour la France constate que le marché de Salesforce en France a connu une période d’harmonisation, les entreprises du marché françai...
Expro Group Holdings N.V. Announces First Quarter 2024 Results
HOUSTON--(BUSINESS WIRE)-- Expro Group Holdings N.V. (NYSE: XPRO) (the “Company” or “Expro”) today reported financial and operational results for the three months ended March 31, 2024. First Quarter 2024 Highlights Revenue was $383 million compared to revenue of $407 million in the fourth quarter of 2023, a decrease of $24 million, or 6%, driven by lower activity primarily in the North and Latin America (“NLA”) and Europe and Sub-Saharan Africa (“ESSA”) segments, partially offset by higher revenue in the Middle East and North Africa (“MENA”). Consistent with historical patterns, revenue a...
Amwell to Participate in Upcoming Investor Conference
Amwell to Participate in Upcoming Investor Conference Boston, April 25, 2024 (GLOBE NEWSWIRE) -- ® (NYSE: AMWL), a leader in hybrid care enablement, announced that the company will participate in the Needham Technology, Media and Consumer Conference. Robert Shepardson, Amwell chief financial officer, will participate in a fireside chat on Tuesday, May 14, at a time to be determined, along with one-on-one investor meetings throughout the day. An audio webcast of the fireside chat will be available at About Amwell Amwell is a leading hybrid care delivery enablement platform ...
Microbix Collaborator Introduces New Lab Accreditation Program
Microbix Collaborator Introduces New Lab Accreditation Program Microbix Product Supporting Testing for Drug-Resistant Sexually-Transmitted Infection MISSISSAUGA, Ontario, April 25, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that Labquality Ltd., a collaborator and customer, is presenting results of its use of Microbix Quality Assessment Products (“QAPs™”) for accreditation of clinical labs for conducting molecular (“MDx”) tests for antimicrobial-resistant (“AMR”) strains of M. ge...
Morphic Announces Corporate Highlights and Financial Results for the F...
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024 - Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Appointed Dr. Simon Cooper as Chief Medical Officer- -Anticipate dosing first patient in GARNET Phase 2 study of MORF-057 in patients with moderate-to-severe Crohn’s disease in second quarter- -Ended first quarter with $658.8 million in cash, cash equivalents, and marketable securities; cash runway into second half of 2027- WALTHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- (Na...
American Airlines Reports First-Quarter 2024 Financial Results
American Airlines Reports First-Quarter 2024 Financial Results FORT WORTH, Texas, April 25, 2024 (GLOBE NEWSWIRE) -- American Airlines Group Inc. (NASDAQ: AAL) today reported its first-quarter 2024 financial results, including: Record first-quarter revenue of approximately $12.6 billion.First-quarter net loss of $312 million, or ($0.48) per diluted share. Excluding net special items1, first-quarter net loss of $226 million, or ($0.34) per diluted share.Achieved best-ever first-quarter completion factor. Generated operating cash flow of $2.2 billion and free cash flow2 of $1.4 billion in ...
Stericycle, Inc. Reports Results For The First Quarter 2024
Stericycle, Inc. Reports Results For The First Quarter 2024 BANNOCKBURN, Ill., April 25, 2024 (GLOBE NEWSWIRE) -- Stericycle, Inc. (Nasdaq: SRCL) today reported results for the first quarter ended March 31, 2024. Revenues for the first quarter were $664.9 million, a decrease of 2.8% compared to $684.3 million in the first quarter of 2023. Income from operations was $38.9 million compared to $40.0 million in the first quarter of 2023. Net income was $13.1 million, or $0.14 diluted earnings per share, compared to $11.2 million, or $0.12 in the first quarter of 2023. Adjusted income...
Optinose Provides Corporate Update on XHANCE Launch and Outlook and An...
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern Time YARDLEY, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced corporate updates detailing its commercial plans and expectations for XHANCE® (fluticasone propionate) following the recent FDA approval of a new indication for the treatment of...
Connectone Bancorp, Inc. Reports First Quarter 2024 Results; Declares ...
Connectone Bancorp, Inc. Reports First Quarter 2024 Results; Declares Preferred and Increased Common Dividends ENGLEWOOD CLIFFS. N.J., April 25, 2024 (GLOBE NEWSWIRE) -- ConnectOne Bancorp, Inc. (Nasdaq: CNOB) (the “Company” or “ConnectOne”), parent company of ConnectOne Bank (the “Bank”), today reported net income available to common stockholders of $15.7 million for the first quarter of 2024 compared with $17.8 million for the fourth quarter of 2023 and $23.4 million for the first quarter of 2023. Diluted earnings per share were $0.41 for the first quarter of 2024 compared with $0.46 fo...
Climb Channel Solutions Launches Partnership with Automox, Providing L...
Climb Channel Solutions Launches Partnership with Automox, Providing Leading Endpoint Management Solution to North American Partners EATONTOWN, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB), announced the launch of a new partnership with Automox, a leading cloud-native IT automation endpoint management solution, now available to their North American partners. With the addition of Automox, Climb partners can provide customers the capabilities to ...
Ultralife Corporation Reports First Quarter Results
Ultralife Corporation Reports First Quarter Results NEWARK, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the first quarter ended March 31, 2024 with the following highlights: Sales of $41.9 million representing a 31.4% year-over-year increase, including 54.7% growth in medical market salesGross profit of $11.5 million, or 27.4% of revenue, compared to $7.4 million, or 23.3% of revenue for the 2023 first quarterOperating income of $4.1 million versus breakeven for the 2023 first quarterGAAP EPS of $0.18 compared to a loss of ...
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generatio...
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases Mammoth’s proprietary ultracompact CRISPR-based gene editing platform and Regeneron’s proprietary delivery technologies set to advance in vivo programs in multiple tissue and cell types Mammoth to receive $100 million total upfront payment and equity investment from Regeneron at signing TARRYTOWN, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Mammoth Biosciences, Inc., today announced a collaboration to research, develop and...
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on...
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024 NEW HAVEN, Conn., April 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its first quarter 2024 financial results on Thursday, May 9, 2024, before the open of the U.S. financial markets. BioXcel Therapeutics’ management team will also host a conference call and webcast at 8:00 AM ET that day to discuss the Company’s...
Plug Signs Additional BEDP Contracts for a Total of 4.5GW of Electroly...
Plug Signs Additional BEDP Contracts for a Total of 4.5GW of Electrolyzers Across Europe and the United States Expanding Basic Engineering and Design Package (BEDP) Portfolio with an additional 350MW of electrolyzers LATHAM, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, has signed two additional contracts to deliver Basic Engineering and Design Packages (BEDP) for projects in Europe and the U.S. with a combined capacity of up to 350 megawatts (MW) of electrolyzers. These agreem...
OTC Markets Group Welcomes Roth CH Acquisition Co. to OTCQX
OTC Markets Group Welcomes Roth CH Acquisition Co. to OTCQX NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced (OTCQX: USCTF), a special purpose acquisition company, has qualified to trade on the OTCQX® Best Market. Roth CH Acquisition Co. previously traded on NASDAQ. Roth CH Acquisition Co. begins trading today on OTCQX under the symbol “USCTF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on . Trading on the OTCQX Market of...
Cibus to Report First Quarter 2024 Financial Results on May 9, 2024 an...
Cibus to Report First Quarter 2024 Financial Results on May 9, 2024 and Host Conference Call SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report first quarter 2024 financial results on Thursday, May 9, 2024. Cibus’ management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.